Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Liabilities and Shareholders Equity (2020 - 2025)

Candel Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $41.2 million for Q4 2023.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 46.97% to $41.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $217.2 million, a 39.25% decrease, with the full-year FY2023 number at $41.2 million, down 46.97% from a year prior.
  • Liabilities and Shareholders Equity hit $41.2 million in Q4 2023 for Candel Therapeutics, down from $50.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CADL hit a ceiling of $101.6 million in Q1 2022 and a floor of $30.7 million in Q2 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $69.1 million across 4 years, with a median of $72.5 million in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 203.48% in 2022 and later plummeted 46.97% in 2023.
  • Tracing CADL's Liabilities and Shareholders Equity over 4 years: stood at $38.3 million in 2020, then soared by 133.02% to $89.2 million in 2021, then fell by 12.91% to $77.7 million in 2022, then tumbled by 46.97% to $41.2 million in 2023.
  • Business Quant data shows Liabilities and Shareholders Equity for CADL at $41.2 million in Q4 2023, $50.1 million in Q3 2023, and $58.7 million in Q2 2023.